drugset / Trial / NCT07053215
Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized controlled trial investigated the efficacy and safety of argon-helium cryoablation combined with PD-1 inhibitors compared to PD-1 inhibitors plus chemotherapy for treating non-small cell lung cancer (NSCLC). The study aimed to evaluate differences in survival, tumor response, immune function, and adverse events.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Comparator | Gemcitabine | Small molecule | 1250 mg/m2 | Intravenous |
| Comparator | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Background | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |